Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07311564 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of LAD603 in Adults With Alopecia Areata

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion pushed from May 23, 2027 to Jun 23, 2027v3
  2. Primary completion date: Sep 6, 2027 to May 23, 2027 Completion date: Sep 6, 2027 to Nov 21, 2027v2 Show 1 more changeShow less
    • Completion date: Sep 6, 2027 to Nov 21, 2027
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main aim of the study is to evaluate the effect of LAD603 in adult participants with severe to very severe alopecia areata (AA). The study will also evaluate the safety, pharmacokinetics (PK), immunogenicity and pharmacodynamic (PD) biomarkers of LAD603.
Trial Details
NCT Number NCT07311564
Lead Sponsor Almirall, S.A.
Conditions Alopecia Areata
Enrollment 136 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov